Oscar Health (OSCR) Loses 12.7% as Wells Fargo Downgrades Stock

Oscar Health, Inc. (NYSE:OSCR) is one of the stocks drowned heavily. Are you holding any?

Oscar Health declined by 12.7 percent week-on-week as investor sentiment was dampened anew by another rating downgrade for its stock.

Last week, Wells Fargo lowered its stock rating and price target for Oscar Health, Inc. (NYSE:OSCR) to “underweight” from “equal weight” and to $10 from $16 previously, amid concerns about rising medical costs and inadequate pricing for 2025. The new price marked a 30.4-percent downside from its latest closing price of $14.38.

This followed Barclays’ first coverage of Oscar Health, Inc. (NYSE:OSCR) on July 2, assigning the firm with an “underweight” rating but with a price target higher than Wells Fargo’s, of $17 apiece.

According to Barclays, its coverage reflected policy risks that could derail the insurer’s ambitious margin and growth targets.

It can be recalled that Oscar Health, Inc. (NYSE:OSCR), under new leadership, set a goal of more than $2.25 earnings per share by 2027.

While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.